In conclusion, among patients with T2D and concomitant cardiovascular disease, treatment with SGLT2-I and GLP-1 RA is associated with a significant survival benefit, with the greatest effect observed in those receiving combination therapy. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.